

Supplementary Table 8. Summary of drug repositioning for MASLD and supporting evidence

Drug	P-value	Hepatotoxicity	Experimental evidence for MASLD	Experimental evidence for other liver diseases	Clinical evidence for MASLD	Clinical evidence for other liver diseases
Imatinib	0.001184	None	30333571			
Erlotinib	0.002979	None	29038049			19139433
Estrone	0.003286	None				
Methyltestosterone	0.005522	None				
Obeticholic acid	0.006746	Exist				
Nitrofurantoin	0.007134	Exist				
Lomustine	0.013728	None				
Vitamin A	0.014435	None	32698042			28371374
Sorafenib	0.014484	Exist				
Valproic acid	0.020411	Exist				
Carbamazepine	0.020728	Exist				
Thalidomide	0.020886	None	20088867			
Verteporfin	0.020933	None	33964370	34101869		
Thrombin	0.022971	None	25138021			
Dexamethasone	0.042834	None	27784782			

The numbers shown in the table represent PubMed Identifier (PMID) numbers, which provide evidence for the foundational research and clinical studies supporting the therapeutic effects of the respective drugs.

MASLD, Non-alcoholic fatty liver disease.